www.urologiepropraxi.cz / Urol. praxi. 2024;25(4):185-193 / UROLOGIE PRO PRAXI 193 PŘEHLEDOVÉ ČLÁNKY Diabetes mellitus z pohľadu urológa litou) zastaviť. Niektoré urologické prejavy (balanopostitída, ED, dysfunkčné močenie a pod.) môžu byť vôbec prvými signálmi diabetu. Pacientov prospech je prvoradý a medziodborová spolupráca zdravotníkov viacerých špecializácií (urológ, diabetológ, nefrológ, röntgenológ, mikrobiológ, rehabilitačný pracovník a pod.) je logickou nutnosťou. LITERATÚRA 1. Lotti F, Maggi M. Effects of diabetes mellitus on sperm quality and fertility outcomes: clinical evidence. Andrology, 2023; 11:399-416. https://doi.org/10.1111/andr.13342. 2. Dillon B, Ang L, Pop-Busui R. Spectrum of diabetic neuropathy: new insights in diagnosis and treatment. Annu Rev Med. 2024;75:293-306. 3. Bonkat G, Bartoletti R, Bruyere F, et al. EAU guidelines on urological infections. https://uroweb.org/guidelines, prístup od 10. 4. 2024. 4. Ryšánková M. Urologické komplikace diabetu. Vnitř Lék, 2023;69(2):E26-E30. 5. Ryšánková M, Hurtová M. Urologické nemoci u diabetického pacienta. Urol Praxi. 2022;23(2):58-65. 6. Cooper K, Badalato G, Rutman M. Infections of the urinary tract. In: Partin A, Dmochowski R, Kavoussi L, et al. Campbell – Walsh Urology, 12th edition, Saunders Elsevier 2021; ISBN 978-0-323-54642-3: 1129-1201. 7. Marenčák J. Pacient s diabetes mellitus v urologickej ambulancii. Via pract, 2023;20(3):104-111. 8. Papp S, Zimmern P. Recurrent urinary tract infections and type 2 diabetes mellitus: a systematic review predominantly in women. Fron Urol, 2023;3:1275334. doi: 10.3389/fruro.2023.1275334. 9. Karslioglu M, Yilmaz M. Exploring the nexus: prevalence, risk factors, and clinical correlations of urinary tract infections in diabetes mellitus patients – a comprehensive retrospective analysis. Annatolian Curr Med J. 2024;6(1):93-96. 10. Bishoff J, Rastinehad A. Urinary tract imaging – basic principles of CT, MRI, and plain film imaging. In: Partin A, Dmochowski R, Kavoussi L, et al. Campbell – Walsh Urology, 12th edition, Saunders Elsevier 2021; ISBN 978-0-32354642-3: 28-67. 11. Marenčák J. Emfyzematózna pyelonefritída. Lek listy. 2020;25(6):5-7. 12. Kawaguchi Y, Mori, Izumi Y, et al. Renal papillary necrosis with diabetes and urinary tract infection. Intern Med, 2018; 57(22):3343 doi: 10.2169/internalmedicine. 13. Marenčák J. Fournierova gangréna. Medical practice. 2021;26(4):16-19. 14. Bhatia S. Multidrug resistant urinary tract infection. In: Khera R. Update on urinary tract infection. Jaypee Brothers Medical Publishers Ltd. 2018; ISBN 978-93-5270-172-8: 111-123. 15. Marenčák J. Uroinfekcia z hľadiska bakteriálnej rezistencie. Via Practica. 2021;18(1):27-32. 16. Naber K, Tirán-Sacedo J, Wagenlehner F. Psychosocial burden of recurrent uncomplicated urinary tract infections. GMS Inf Dis. 2022;10(1):1-9. 17. Marenčák J. Súčasný manažment recidivujúcich, nekomplikovaných zápalov dolných močových ciest u žien. Klin Urol. 2023;19(3):116-124. 18. Mulawkar P. Emphysematous pyelonephritis. In: Khera R. Update on urinary tract infection. Jaypee Brothers Medical Publishers Ltd. 2018; ISBN 978-93-5270-172-8: 32-49. 19. Marenčák J. Bakteriálna prostatitída. Lek listy. 2021;26(6): 12-15. 20. Tallai B, Gulistan T, Alrayashi M, et al. A rare presentation of renal papillary necrosis in a COVID-19-positive patients. Case Rep Urol, 2021; 6611861. doi: 10.1155/2021/6611861. 21. Radcliffe R, Khan M. Mortality associated with Fournier´s gangrene remains unchanged over 25 years. BJU Int, 2020;125(4):610-616. 22. Insua-Pereira I, Ferreira P, Teixeira E, et al. Fournier´s gangrene: a review of reconstructive options. Cent Eur J Urol. 2020;73(1):74-79. 23. Huang C, Lien C, Lee S, et al. Adult balanoposthitis patients have a higher risk of type 2 diabetes mellitus: a nationwide population based cohort study. Urol Sci. 2018;29(1):55-60. 24. Agró E, Rosato E, Wagg A, et al. How to make progress in phenotyping patients with LUT such as OAB and underactive detrusor, including using markers and microbiome data, in order to personalize therapy? ICI-RS 2023: Part 1. Neurol Urodyn. 2024;1-11. doi: 10.1002/nau.25377. 25. Khan J, Shaw S. Risk of multiple lower and upper urinary tract problems among male older adults with type-2 diabetes: a population based study. The Aging Male. 2023;26:1, 2208658, DOI: 10.1080/13685538.2023.2208658. 26. Xin C, Fan H, Xie J, et al. Impact of diabetes mellitus on lower urinary tract symptoms in benign prostatic hyperplasia patients: a meta – analysis. Front Endocrinol (Lausanne), 2022; 12:741748.doi: 10.3389/fendo.2021.741748. eCollection 2021. 27. Jo J, Kim H, Bang W, et al. Effect of diabetes mellitus on symptomatic improvement after surgery for benign prostatic hyperplasia in patients with lower urinary tract symptoms and its relations with prostatic urethral angulation. Int Neurourol J. 2023;27(2):116-123. 28. Eskidemir U, Simsir A, Simsir I, et al. Evaluation of lower urinary tract functions in diabetic patients. J Urol Surg. 2019;6(1):46-53. 29. Cornu J, Gacci M, Hashim H, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS). https://uroweb.org/guidelines, prístup od 10. 4. 2024. 30. Fwu Ch, Schulman I, Lawrence J, et al. Association of obesity, metabolic syndrome, and diabetes with urinary incontinence and chronic kidney disease: analysis of the national health and nutrition examination survey, 2003–2020. J Urol. 2024; 211: 124-133. https://doi.org/10.1097/JU.0000000000003761. 31. Augustine J, Wee A, Krishnamurthi V, et al. Renal insufficiency and ischemic nephropathy. In: Partin A, Dmochowski R, Kavoussi L, et al. Campbell – Walsh Urology, 12th edition, Saunders Elsevier 2021; ISBN 978-0-323-54642-3: 1921-1935. 32. DeLay K, Haney N, Hellstrom W. Modifying risk factors in the management of erectile dysfunction: a review. World J Mens Health. 2016;34(2):89-100. 33. Salonia A, Bettocchi C, Capogrosso P, et al. EAU guidelines on sexual and reproductive health.). https://uroweb.org/ guidelines, prístup od 10. 4. 2024. 34. Burnett A, Ramasamy R. Evaluation and management of erectile dysfunction. In: Partin A, Dmochowski R, Kavoussi L. et al. Campbell – Walsh Urology, 12th edition, Saunders Elsevier 2021; ISBN 978-0-323-54642-3: 1513-1538. 35. Blair Y, Doherty L, Temprosa M, et al. Prevalence and predictors of erectile dysfunction among men in the diabetes prevention program outcome study. J Diabetes Complications. 2024;38(2):108669. 36. Niederberger C, Ohlander S, Pagani R. Male infertility. In: Partin A, Dmochowski R, Kavoussi L. et al. Campbell – Walsh Urology, 12th edition, Saunders Elsevier 2021; ISBN 978-0323-54642-3: 1428-1452. 37. Huang R, Chen J, Guo B, et al. Diabetes – induced male infertility: potential mechanisms and treatment options. Mol Med. 2024;30:11, https://doi.org/10.1186/s10020-023-00771-x. 38. Strohmaier W. Infection induced urinary stones. In: Bjerklund-Johannsen T, Wagenlehner F, Matsumoto T. et al. Urogenital infections and inflammations. Duesseldorf: GMS 2017; DOI: 10.5680/lhuii000017-25. 39. Skolarikos A, Jung H, Neisius A, et al. EAU guidelines on urolithiasis. https://uroweb.org/guidelines, prístup od 10. 4. 2024. 40. Rašiová M, Kozárová M. Diabetes mellitus a malígne nádory. Int med. 2013;13(1):29-33. 41. Cornford P, Tilki D, van den Bergh R, et al. EAU-EANM- -ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. https://uroweb.org/guidelines, prístup od 10. 4. 2024. 42. Witjes J, Bruins H, Carrión A, et al. EAU guidelines on muscle invasive and metastatic bladder cancer. https://uroweb. org/guidelines, prístup od 10. 4. 2024. 43. Lee H, Song B, Kwak C, et al. Diabetes mellitus as an independent predictor of survival of patients surgically treated for renal cell carcinoma: a propensity score matching study. Eur Urol Suppl. 2016;15(3):e978. 44. Akshay J. Top 5 medications that can increase blood glucose levels. Medscape, Jan 30, 2024. 45. Lin E, Garmo H, Hemelrijck M, et al. Diabetes control in men with type 2 diabetes mellitus and prostate cancer treated with GnRH agonists: a nationwide, population – based cohort study. Eur Urol. 2021;79(S1):S1188. 46. Merseburger A, Bahl A, Sodatonou H, et al. New or worsening type 2 diabetes mellitus (T2DM) in men treated with enzalutamide (ENZ) or abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): EVADE study. EMUC23: Poster session, 15th European Multidisciplinary Congress on Urological Cancers, 04 November 2023; P:111. 47. Adil M, Khan R, Ghosh P, et al. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: a systematic literature review and meta-analysis of observational studies using real-world data. Clin Epidem and Glob Health. 2018;6(2):61-68. 48. Margel D, Urbach D, Lipscombe L, et al. Metformin use in all cause and prostate cancer specific mortality among men with diabetes. J Clin Oncol. 2013;31(25):3069-3075. 49. Chang C, Wang C, Jhan J, et al. The protective effect of metformin in upper tract urothelial carcinoma patients with type 2 diabetes. Eur Urol. 2021;79(S1):S1100. 50. Paik J, Tesfaye H, Curhan G, et al. Sodium – glukose cotransporter 2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes. Jama Intern Med. 2024;184(3):265-274.
RkJQdWJsaXNoZXIy NDA4Mjc=